Kag - I was not referring to the approval process with the FDA, I was talking about the development of the technology within Abbott's Architect Platform. Allow me to present my ? like this: When Abbott further develops the technology and incorporates it into their Architect Platform, will the diagnosis for prostate be the same assay that would identify any and all types of cancer? My original post assumed that Abbott would have to develop an assay for each cancer type, but perhaps that is not the case!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.